Group One Trading’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-4
| Closed | -$1 | – | 8517 |
|
|
2023
Q3 | $1 | Hold |
4
| – | – | ﹤0.01% | 7548 |
|
|
2023
Q2 | $5 | Hold |
4
| – | – | ﹤0.01% | 7566 |
|
|
2023
Q1 | $7 | Hold |
4
| – | – | ﹤0.01% | 7097 |
|
|
2022
Q4 | $13 | Sell |
4
-1
| -20% | -$6 | ﹤0.01% | 7115 |
|
|
2022
Q3 | $0 | Hold |
5
| – | – | ﹤0.01% | 8712 |
|
|
2022
Q2 | $0 | Hold |
5
| – | – | ﹤0.01% | 8962 |
|
|
2022
Q1 | $0 | Sell |
5
-2
| -29% | -$369 | ﹤0.01% | 9142 |
|
|
2021
Q4 | $2K | Hold |
7
| – | – | ﹤0.01% | 7953 |
|
|
2021
Q3 | $5K | Buy |
7
+2
| +40% | +$1.74K | ﹤0.01% | 7786 |
|
|
2021
Q2 | $6K | Hold |
5
| – | – | ﹤0.01% | 7734 |
|
|
2021
Q1 | $10K | Buy |
5
+1
| +25% | +$2K | ﹤0.01% | 7072 |
|
|
2020
Q4 | $5K | Buy |
+4
| New | +$8.18K | ﹤0.01% | 6064 |
|
|
2020
Q2 | – | Sell |
-2
| Closed | -$9.6K | – | 6396 |
|
|
2020
Q1 | $7K | Buy |
+2
| New | +$18.9K | ﹤0.01% | 4706 |
|
Group One Trading's BXRX Position: Q4 2023 in Review
Group One Trading sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2023, closing a stake of 4 shares — an estimated $1 sold.
Group One Trading first reported a position in BXRX in Q1 2020 and held it in 13 quarters. The position peaked at $10K in Q1 2021. 2 funds tracked by Wall St. Rank hold BXRX as of Q4 2023.
- Group One Trading reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Group One Trading sold 4 Baudax Bio, Inc. Common Stock shares in Q4 2023, an estimated $1.
- Group One Trading first reported a position in Baudax Bio, Inc. Common Stock in Q1 2020 and held it in 13 quarters.
- Group One Trading's Baudax Bio, Inc. Common Stock position peaked at $10K in Q1 2021.
- 2 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2023.
Based on Group One Trading's 13F filing for Q4 2023, filed 14 Feb 2024.